FDA Watch

Agency to Use EUA Pathway to Clear New Coronavirus Detection Tests

There are no FDA-cleared tests to detect the new 2019-nCoV Wuhan coronavirus. But on Jan. 28, the agency unveiled its strategy to promote the rapid development and availability of safe and effective investigational medical products “to address this urgent public health situation.”

As with previous infectious disease outbreaks like Zika, the FDA will clear new 2019-nCoV tests and treatment products on an expedited basis via the Emergency Use Authorization (EUA) pathway. The FDA is calling on diagnostic test sponsors interested in potential EUA for detection tests to contact the Center for Devices and Radiological Health (CDRH) (CDRH-EUA-Templates@fda.hhs.gov) for information and templates.

The FDA has also created a landing page to keep product developers and the public informed about the outbreak and the FDA’s  response measures.

CLOSE TO VIEW ARTICLE x

You have 9 articles left to view this month.

Your 3 Free Articles Per Month Goes Very Quickly!
Get a 3 month Premium Membership to
one of our G2 Newsletters today!

Click on one of the Newsletters below to sign up now and get unlimited access to all articles, archives, and tools for that specific newsletter!

Close

EMAIL ADDRESS


PASSWORD
EMAIL ADDRESS

FIRST NAME

LAST NAME

TITLE

COMPANY

PHONE

Try Premium Membership

(-00000g2)